Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

CMS Medicaid Director Departs Amid Republican Push for Program Cuts

CMS Medicaid Director Departs Amid Republican Push for Program Cuts

Drew Snyder, the Trump administration's Medicaid director, is set to leave his position at the Centers for Medicare & Medicaid Services (CMS) as Republicans intensify efforts to implement substantial cuts to the Medicaid program. The departure, reported by Politico, comes at a critical juncture for the future of Medicaid funding and policy.

NoahAI News6/4/2025
Plexium Restructures to Focus on Protein Degrader Pipeline

Plexium Restructures to Focus on Protein Degrader Pipeline

Plexium, a San Diego-based protein degradation company, has initiated a strategic realignment of its resources to better support its advancing development stage pipeline. The restructuring involves staff reductions across various departments, affecting employees ranging from associate to senior and principal scientists.

NoahAI News6/4/2025
BioAge Labs Reenters Weight Loss Arena with Chinese Biotech Partnership

BioAge Labs Reenters Weight Loss Arena with Chinese Biotech Partnership

BioAge Labs, a Bay Area biotech company, has announced a new strategic move in the competitive weight loss market, signaling its commitment to obesity treatment despite recent setbacks. The company has entered into an option agreement with Chinese firm JiKang Therapeutics for a novel apelin receptor (APJ) agonist nanobody, potentially expanding its portfolio of obesity-fighting compounds.

NoahAI News6/4/2025
Gen Z Recruitment in Pharma: Social Media Strategies and Industry Awareness

Gen Z Recruitment in Pharma: Social Media Strategies and Industry Awareness

The pharmaceutical industry is facing challenges in attracting young talent, with a new report from the Association of the British Pharmaceutical Industry (ABPI) highlighting the need for innovative recruitment strategies targeting Generation Z. The report, based on surveys of 16- to 25-year-olds, STEM teachers, and career counselors in the UK, reveals a significant lack of understanding about the pharmaceutical industry among young job seekers and suggests leveraging social media platforms to bridge this knowledge gap.

NoahAI News6/4/2025
Political Climate and Job Market Concerns Drive Biopharma Professionals to Consider Work Abroad

Political Climate and Job Market Concerns Drive Biopharma Professionals to Consider Work Abroad

A recent survey by BioSpace reveals a significant trend in the biopharmaceutical industry: a substantial number of professionals are contemplating leaving the United States to pursue career opportunities abroad. This shift is primarily driven by concerns over the current political climate and challenges in the domestic job market.

NoahAI News5/29/2025
Medtech IPO Window Shows Signs of Opening After Three-Year Drought

Medtech IPO Window Shows Signs of Opening After Three-Year Drought

After a prolonged period of inactivity, the medical technology industry is seeing a resurgence in initial public offerings (IPOs), potentially signaling the end of a three-year drought. Recent months have witnessed a small burst of activity, with several companies successfully going public and raising substantial funds. However, the volatile economic landscape and lingering uncertainties continue to complicate the decision-making process for firms considering an IPO.

NoahAI News5/29/2025
Daiichi Sankyo and Merck Withdraw HER3-DXd FDA Filing Amid Clinical Trial Setback

Daiichi Sankyo and Merck Withdraw HER3-DXd FDA Filing Amid Clinical Trial Setback

Daiichi Sankyo and Merck & Co. have voluntarily withdrawn their Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) from the U.S. Food and Drug Administration (FDA). This decision comes after a phase 3 confirmatory trial failed to meet its overall survival endpoint, dealing a significant blow to the companies' ambitions in the non-small cell lung cancer (NSCLC) treatment landscape.

NoahAI News5/29/2025
Intellia's Gene Therapy Faces Setback as Patient Experiences Grade 4 Adverse Event

Intellia's Gene Therapy Faces Setback as Patient Experiences Grade 4 Adverse Event

Intellia Therapeutics, a prominent player in the gene therapy arena, has encountered a significant challenge in its ongoing phase 3 trial for the drug candidate nex-z. The company's stock took a substantial hit following the disclosure of a grade 4 adverse event in a patient, raising concerns about the therapy's safety profile. Despite this setback, analysts remain optimistic about the treatment's potential.

NoahAI News5/29/2025
FDA Rejects Stealth BioTherapeutics' Elamipretide for Barth Syndrome, Company Plans Resubmission

FDA Rejects Stealth BioTherapeutics' Elamipretide for Barth Syndrome, Company Plans Resubmission

Stealth BioTherapeutics faced a setback as the U.S. Food and Drug Administration (FDA) rejected its application for elamipretide, a peptide targeting mitochondria, in the treatment of Barth syndrome. The Massachusetts-based biotech company, however, remains optimistic as the agency outlined a potential path to accelerated approval.

NoahAI News5/29/2025
HHS Terminates Moderna's $590M Bird Flu Vaccine Contract, Impacting Late-Phase Development

HHS Terminates Moderna's $590M Bird Flu Vaccine Contract, Impacting Late-Phase Development

The Department of Health and Human Services (HHS) has terminated a $590 million contract with Moderna for the late-stage development of a pandemic bird flu vaccine, raising questions about the future of the biotech's influenza program. This decision comes amid leadership changes at HHS and ongoing debates surrounding mRNA vaccine technology.

NoahAI News5/29/2025
Cancer Drugmaker iTeos to Shut Down, Highlighting Industry Challenges

Cancer Drugmaker iTeos to Shut Down, Highlighting Industry Challenges

In a stark reminder of the challenges facing the biotech industry, cancer drugmaker iTeos Therapeutics announced plans to wind down operations and sell off its assets. This move comes just weeks after the company shelved its most advanced drug prospect, a TIGIT-targeting treatment developed in partnership with GSK.

NoahAI News5/29/2025
Veru's Muscle-Sparing Obesity Drug Enobosarm Shows Promise in Phase 2 Trial

Veru's Muscle-Sparing Obesity Drug Enobosarm Shows Promise in Phase 2 Trial

Veru Inc. has reported positive safety results from a Phase 2 clinical trial of its muscle-preserving obesity drug enobosarm, paving the way for a planned Phase 3 study. The trial, which combined enobosarm with Novo Nordisk's popular weight-loss medication Wegovy, demonstrated potential benefits in reducing gastrointestinal side effects and preserving lean muscle mass in older adults with obesity.

NoahAI News5/29/2025
«1...606162...67»